$0.29
4.66% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US40423R1059
Symbol
HCWB
Sector
Industry

HCW Biologics Inc Stock price

$0.29
-0.29 49.21% 1M
-0.87 74.60% 6M
-0.93 75.95% YTD
-0.63 67.98% 1Y
-2.67 90.05% 3Y
-6.01 95.32% 5Y
-6.01 95.32% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.01 4.66%
ISIN
US40423R1059
Symbol
HCWB
Sector
Industry

Key metrics

Market capitalization $11.14m
Enterprise Value $12.85m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 3.67
P/S ratio (TTM) P/S ratio 3.18
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 22.27%
Revenue (TTM) Revenue $3.50m
EBIT (operating result TTM) EBIT $-24.45m
Cash position $1.16m
EPS (TTM) EPS $-1.00
P/E forward negative
P/S forward 15.52
EV/Sales forward 23.38
Short interest 0.04%
Show more

Is HCW Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

HCW Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast HCW Biologics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast HCW Biologics Inc:

Buy
100%

Financial data from HCW Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.50 3.50
22% 22%
100%
- Direct Costs - -
-
-
1.13 1.13
369% 369%
32%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 7.24 7.24
6% 6%
207%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -24 -24
19% 19%
-698%
Net Profit -37 -37
89% 89%
-1,067%

In millions USD.

Don't miss a Thing! We will send you all news about HCW Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

HCW Biologics Inc Stock News

Neutral
GlobeNewsWire
one day ago
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quar...
Neutral
GlobeNewsWire
3 months ago
This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows: MIRAMAR, Fla.
Neutral
GlobeNewsWire
3 months ago
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second qua...
More HCW Biologics Inc News

Company Profile

HCW Biologics, Inc. operates as a holding company which engages in the research and development of immunotherapies. It focuses on cancer and aging-associated diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

Head office United States
CEO Hing Wong
Employees 45
Founded 2018
Website www.hcwbiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today